Anti-CD123-CAR-transduced T cells

Anti-CD123-CAR-transduced T cells represent a type of adoptive cell therapy where T lymphocytes are genetically engineered to express a Chimeric Antigen Receptor (CAR) specifically designed to target the CD123 antigen. CD123, also known as the interleukin-3 receptor alpha chain (IL3RA), is a cell surface protein that is highly expressed on various hematological cancer cells, including those found in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), while its expression is low or absent on normal hematopoietic stem cells. This differential expression makes CD123 an attractive target for cancer immunotherapy. Upon administration, these modified T cells recognize and bind to CD123-expressing tumor cells, leading to T cell activation, secretion of inflammatory cytokines, and subsequent lysis of the cancer cells. The CAR construct typically includes an extracellular CD123-binding single-chain variable fragment (scFv) and intracellular signaling domains, often incorporating co-stimulatory molecules like 4-1BB (CD137) or CD28 to enhance T cell activation and persistence. This therapeutic approach aims to provide a targeted and potent anti-tumor immune response for patients with hematological malignancies.

Other names

CD123-CAR T cellsCD-123-CAR T cellsCD 123-CAR T cellsAnti-CD123 CAR-T cellsAnti-CD-123 CAR-T cellsAnti-CD 123 CAR-T cellsCD123-specific CAR T-cell therapyCD-123-specific CAR T-cell therapyCD 123-specific CAR T-cell therapyAutologous Anti-CD123 CAR TCR/4-1BB-expressing T-lymphocytes